Werewolf <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Faces Nasdaq Noncompliance After Audit Committee Member's Passing; Plans to Regain Compliance
**Werewolf Therapeutics Announces Noncompliance with Nasdaq Listing Rule Following Board Member's Passing** Werewolf Therapeutics Inc. disclosed that it is no longer in compliance with Nasdaq Listing Rule 5605(c)(2) after the passing of Dr. Alon Lazarus, a member of its Board of Directors, on September 30, 2025. Dr. Lazarus's death reduced the number of independent directors on the company's Audit Committee to two, below the required minimum of three. The company notified Nasdaq of the noncompliance on October 2, 2025, and is entitled to a cure period that extends until its next annual stockholder meeting or September 30, 2026, whichever comes first. Werewolf Therapeutics stated it intends to restore compliance by appointing a new independent director as soon as possible.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-231953), on October 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.